Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: Comparison of efficacy and side effects using odds ratios

Journal of Clinical Pharmacology

Volumn 43, Issue 5, 2003, Pages 491-503

  Lathers, Claire M ^a   Schraeder, Paul L ^b   Claycamp, H Gregg ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Efficacy; Lamotrigine; Odds ratios; Phenobarbital; Safety; Topirimate

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID;

AGITATION; ANGIONEUROTIC EDEMA; ANXIETY; APNEA; ATAXIA; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DIPLOPIA; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPILEPSY; EXFOLIATIVE DERMATITIS; FEVER; HALLUCINATION; HEADACHE; HUMAN; HYPERKINESIA; HYPOTENSION; HYPOVENTILATION; INSOMNIA; LETHARGY; LIVER INJURY; MEDICAL INFORMATION; MEGALOBLASTIC ANEMIA; MENTAL DISEASE; NAUSEA; NERVOUSNESS; NIGHTMARE; PATIENT COMPLIANCE; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNCOPE; THOUGHT DISORDER; TOXIC EPIDERMAL NECROLYSIS; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

EID: 0347482480     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003251837     Document Type: Review

References (59)

1. McNamara J: Drugs effective in the therapy of the epilepsies, in: Hardman JG, Limbird LE (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill, 2001;521-547.
2. Leestma JE, Annegers JF, Brodie MJ, Brown S, Schraeder PL, Siscovick D, et al: Sudden unexplained death in epilepsy: observations from a large clinical trial. Epilepsia 1997;38:47-55.
3. Lathers CM, Schraeder PL: Experience-based teaching of therapeutics and clinical pharmacology of antiepileptic drugs. J Clin Pharmacol 1995;35:573-587.
4. Schraeder PL, Lathers C: Clinical pharmacology of antiepileptic drug use: "clinical pearls about the perils of Patty." A clinical pharmacology problem solving (CPPS) unit. J Clin Pharmacol 1995;35: 1120-1135.
5. Lathers CM, Schraeder PL: Review of autonomic dysfunction, cardiac arrhythmias, and epileptogenic activity. J Clin Pharmacol 1987;27:346-356.
6. Schraeder PL, Lathers CM, Charles JB: The spectrum of syncope. J Clin Pharmacol 1994;34:454-459.
7. Lathers CM, Schraeder PL: Clinical pharmacology: drugs as a benefit and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 2002;42:123-136.
8. Lathers CM, Schraeder PL, Tumer N: The effect of phenobarbital upon autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. J Clin Pharmacol 1993; 33:837-844.
9. Lathers CM, Schraeder PL: Autonomic dysfunction in epilepsy: characterization of autonomic cardiac neural discharge associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 1982;23:633-648.
10. Schraeder PL, Lathers CM: Cardiac neural discharge and epileptogenic activity in the cat: an animal model for unexplained sudden death. Life Sci 1983;32:1371-1382.
11. Lathers CM, Schraeder PL, Carnel SB: Neural mechanisms in cardiac arrhythmias associated with epileptogenic activity: the effect of phenobarbital. Life Sci 1984;34:1919-1936.
12. 2: explanation for epileptogenic activity and dysfunction in autonomic cardiac neural discharge leading to arrhythmias. Med Hypotheses 1984;15:15-30.
13. Carnel SB, Schraeder PL, Lathers CM: The effect of phenobarbital pretreatment on cardiac neural discharge and pentylenetetrazol-induced epileptogenic activity. Pharmacology 1985;20:225-240.
14. Lipka LJ, Lathers CM: Psychoactive agents, seizure production, and sudden death in epilepsy. J Clin Pharmacol 1987;27:169-183.
15. Lathers CM, Schraeder PL, Weiner FL: Synchronization of cardiac autonomic neural discharge with epileptogenic activity: the lock step phenomenon. Electroencephalography and Clinical Neurophysiology 1987;67:247-259.
16. Kraras CM, Tumer N, Lathers CM: The role of neuropeptides in the production of epileptogenic activity and autonomic dysfunction: origin of arrhythmia and sudden death in the epileptic patient? Med Hypotheses 1987;23:19-31.
17. 2-methionine enkephalinamide and naloxone on cardiovascular parameters in the cat. Life Sci 1988;43:2287-2298.
18. Schraeder PL, Lathers CM: Paroxysmal cardiovascular dysfunction and epileptogenic activity. Epilepsy Res 1989;3:55-62.
19. Stauffer AZ, Dodd-o J, Lathers CM: The relationship of the lockstep phenomenon and precipitous changes in mean arterial blood pressure. Electroencephalography and Clinical Neurophysiology 1989;72:340-345.
20. Lathers CM, Jim KF, Spivey WH: A comparison of intraosseous and intravenous routes of administration for antiseizure agents. Epilepsia 1989;30:472-479.
21. Jim KF, Lathers CM, Ferris VL, Pratt LF, Spivey WH: Suppression of pentylenetetrazol elicited seizure activity by intraosseous lorazepam in pigs. Epilepsia 1989;30:480-486.
22. Lathers CM, Stauffer AZ, Tumer N, Kraras CM, Goldman BD: Effect of timolol on the electrocorticogram and cardiovascular parameters associated with pentylenetetrazol-induced epileptogenic activity in the cat. Epilepsy Res 1989;4:42-54.
23. Lathers CM, Schraeder PL: Autonomic dysfunction, cardiac arrhythmias and epileptogenic activity, in: Lathers CM, Schraeder PL (eds.), Epilepsy and Sudden Death. New York: Marcel Dekker, 1990; 135-155.
24. Lathers CM, Schraeder PL: Arrhythmias associated with epileptogenic activity elicited by penicillin, in: Lathers CM, Schraeder PL (eds.), Epilepsy and Sudden Death. New York: Marcel Dekker, 1990;157-167.
25. Lathers CM, Schraeder PL, Boggs JG: Sudden unexplained death and autonomic dysfunction, in: Engel J Jr, Pedley TA (eds.), Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997.
26. Patsalos PN, Sander JW: Newer antiepileptic drugs: towards an improved risk-benefit ratio. Drug Saf 1994;11:37-67.
27. Elger CE, Bauer J: New antiepileptic drugs in epileptology. Neuropsychobiology 1998;38:145-148.
28. Privitera M, Ficker DW, Welty TE: Topiramate. Section B: Specific antiepileptic medications and other therapies, in: Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. New York: Raven, 1995.
29. Shapira NA, Goldsmith TD, McClroy SL: Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-372.
30. Ghaemi SN, Gaughan S: Novel anticonvulsants: a new generation of mood stabilizers? Harvard Rev Psychiatry 2000;8:1-7.
31. Uldall P, Buchholt J: Clinical experiences with topiramate in children with intractable epilepsy. Europ J Paediatr Neurol 1999;3(3): 105-111.
32. Erfurth A, Kuhn G: Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiol 2000;42(Suppl. 1):50-51.
33. Guberman AH, Besag FM, Brodie MJ, Doley JM, Duchowny MS, Pellock JM, et al: Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-991.
34. Meador KJ, Loring DW, Ray PG, Murro AM, King DW, Perrine KR, et al: Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001;56:1177-1182.
35. Selvin S: Statistical Analysis of Epidemiologic Data. 2nd ed. New York: Oxford University Press, 1996.
36. Cramer J, Fisher R, Ben-Menachem E, French J, Mattson R: New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40(5):590-600.
37. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al: A comparison of lorazepam, diazepam, and placebo for treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345: 631-637.
38. Brodie MJ: Drug interactions in epilepsy. Epilepsia 1992; 33(Suppl. 1):S13-S22.
39. Brodie MJ: Monstars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia 1999;40(Suppl. 6):S17-S22.
40. Novak G, Maytal J, Alshansky A, Ascher C: Risk factors for status epilepticus in children with symptomatic epilepsy. Neurol 1997;49: 533-537.
41. Brodie MJ, Dichter MA: Antiepileptic drugs. N Engl J Med 1996; 334:168-175.
42. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B: The VA Epilepsy Cooperative Study Group. Epilepsia 1987; 28(Suppl. 3):S50-S58.
43. Cramer J, Mattson RH: Phenobarbital toxicity, in: Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. 4th ed. New York: Raven, 1995;409-420.
44. Nembutal, in: Physicians'Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co., 2002;485-487.
45. Ben-Menachem E: Potential antiepileptic drugs: topiramate, in: Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. 4th ed. New York: Raven, 1995;1063-1070.
46. Valproate and other anticonvulsants for psychiatric disorders. Med Lett 2000;42:114-115.
47. Harden CL: Practical and pharmacokinetic considerations in the management of refractory partial epilepsy, in: The Protocols Series: Guidelines from Experts in Epilepsy. Number 3. Ghent, NY: Galen Press, 2001:11-13.
48. Two new drugs for epilepsy: oxcarbazepine and levetiracetam. Med Lett 2000;42:33-35.
49. Zonisamide (Zonegran) for epilepsy. Med Lett 2000;42:95.
50. Marsuo F, Bergen D, Frugh E, et al: Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: U.S. Lamotrigine Protocol No. 5. Neurology 1993;43:2284-2291.
51. Gilliam FG, Gidal BE: Lamotrigine, in: Wyllie E (ed.), The Treatment of Epilepsy 3rd ed. Philadelphia: Lippincott, 2001.
52. Leach JP, Brodie MJ: Lamotrigine: clinical use, in: Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. 4th ed. New York: Raven, 1995;889-895.
53. Peck AW: Clinical pharmacology of lamotrigine. Epilepsia 1991;32(Suppl. 2):S9-S12.
54. Lamictal, in: Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co., 2002;1567-1574.
55. Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA: Lamotrigine (BW430C), a potential anticonvulsant: effects on the central nervous system in comparison with pheytoin and diazepam. Br J Clin Pharmacol 1985;20:619-629.
56. Rantala H, Tarkka R, Uhari M: A meta-analytic review of the preventive treatment of recurrences of febrile seizures. J Pediatr 1997; 131:922-925.
57. Toman JEP: Drugs effective in convulsive disorders, in: Goodman LS, Gilman A (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. 3rd ed. New York: Macmillan, 1965;215-236.
58. Woodbury DM, Fingl E: Drugs effective in the therapy of the epilepsies, in: Goodman LS, Gilman A (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan, 1975;201-226.
59. Papakostas YG, Daras MD: Placebos, placebo effect, and the response to the healing situation: the evolution of a concept. Epilepsia 2001;42:1614-1625.